Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Blautia argi
- Development stage
- Preclinical
- Lead developer
- Xi'an Jiaotong University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Blautia argi is an anaerobic bacterial strain within the Blautia genus being investigated as a live biotherapeutic product (LBP) for the treatment of Parkinson's disease. Research has identified that the abundance of Blautia argi is significantly depleted in the gut microbiota of patients with Parkinson's disease. In preclinical models, specifically 6-OHDA-induced rat models, oral administration of Blautia argi has been shown to ameliorate motor impairments and exert neuroprotective effects. These effects include the preservation of tyrosine hydroxylase-positive dopaminergic neurons in the substantia nigra and a reduction in neuroinflammation, characterized by decreased astrocyte proliferation and lower expression of glial fibrillary acidic protein (GFAP). The therapeutic potential of Blautia argi is thought to be mediated through the modulation of the gut-brain axis and systemic anti-inflammatory pathways.
- Other names
- Blautia argi
02
Targets
Gut microbiota
Beyond the preview
Go deeper on Blautia argi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Blautia argi.